Enjoy complimentary customisation on priority with our Enterprise License!
The anti-cd20 monoclonal antibodies (mABs) market size is estimated to grow by USD 11.43 billion accelerating at a CAGR of 10.31% between 2023 and 2028.
Anti-cd20 monoclonal antibodies (mABs) market Share
_market_size_abstract_2023_v1.jpg.webp?v4.1.14)
For More Highlights About this Report, Download Free Sample in a Minute
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increased use of combination therapies is the key factor driving market growth. Combination therapy is often preferred when monotherapy products are less effective and poorly tolerated. The market has witnessed a significant increase in the use of anti-CD20 mABs in combination with other drugs to target comorbidity diseases. Usually, combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, the use of drugs in combination increases the tolerability, as two compounds can be employed below their individual dose thresholds.
Furthermore, the market has witnessed multiple approvals for anti-CD20 mABs as combination therapy for the treatment of various indications in recent years. Hence, the higher efficacy of anti-CD20 mABs when used in combination therapy than monotherapy is anticipated to boost the adoption rate of therapeutics, which will drive the growth of the market during the forecast period.
The development of CD20 bispecific antibodies is the primary trend shaping market growth. Bispecific antibodies are combinations of two or more antigens in one product and are capable of binding to two or more specific targets, through multiple pathways in the target disease. Simultaneous blocking of multiple biological pathways allows bispecific antibodies to exhibit synergistic effects, which is not possible with mixtures of monospecific antibodies.
Moreover, the use of bispecific antibodies makes it possible to optimize expenses by reducing the cost of drug development and clinical trials. Furthermore, due to the dual and synergistic mechanism of these bispecific antibodies, several companies are developing bispecific CD20/CD3 mABs to treat several CD20-positive diseases. Hence, the development of CD20 bispecific antibodies is one of the trends that is anticipated to drive the growth of the market during the forecast period.
Adverse effects of anti-CD20 mABs is a challenge that affects market growth. Although anti-CD20 mABs are widely used to treat CD20-positive conditions, due to their high target affinity and safety profile, serious negative effects associated with their use pose a threat to the development of the global anti-CD20 monoclonal antibodies (mABs) market.
Moreover, some of the serious side effects of anti-CD20 mABs included with Rituximab are chest pain, irregular heartbeats, and kidney problems. With Obinutuzumab are hepatitis B virus reactivation, and hyponatremia. Ocrelizumab increases the risk of respiratory tract infections. Due to serious side effects associated with anti-CD20 mABs, patients prefer alternative treatment options, which may impede the growth of the market during the forecast period.
The product segment includes oncology, neurology, and immunology. The type segment includes first generation anti-CD20 monoclonal antibody, second generation anti-CD20 monoclonal antibody, and third generation anti-CD20 monoclonal antibody. The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW).
The market share growth by the oncology segment will be significant during the forecast period. The growth of the oncology segment is largely due to the availability of anti-CD20 mAb to treat common cancer indications. The high incidence and prevalence of cancer is expected to drive the growth of this segment.
_market_segments_abstract_2023_v2.jpg.webp?v4.1.14)
Get a glance at the market contribution of various segments Download the PDF Sample
The oncology segment was valued at USD 6.73 billion in 2018. However, the growth of this segment is expected to decrease with the introduction of rituximab biosimilars, especially in Europe. The introduction of low-cost biosimilars will hinder the sales of branded drugs, which are highly priced, which, in turn, will limit the growth of the segment in the anti-cd20 monoclonal antibodies market during the forecast period.
_market_regions_abstract_2023_geo_v2.jpg.webp?v4.1.14)
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 57% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The growth of the anti-CD20 monoclonal antibody (mAB) market in North America is due to the high incidence and prevalence of hematological malignancies such as non-Hodgkin lymphoma (NHL).
In addition, the growth of the market in the region is driven by recent approvals for anti-CD20 mABs in the region. Additionally, the anti-cd20 monoclonal antibodies market growth in this region is expected to be driven by the continuous demand for OCREVUS, owing to the increasing incidence and relapsed cases of multiple sclerosis. Furthermore, the expected approval of late-stage pipeline drugs is also estimated to propel the market growth in this region during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amgen Inc.: The company offers anti CD20 monoclonal antibodies such as Bax active monomer recombinant antibody 6A7 OAAV00544 and CD52 recombinant antibody campath 1H OAAV00552.
The research report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
|
Anti-CD20 Monoclonal Antibodies (mABs) Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
161 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.31% |
|
Market growth 2024-2028 |
USD 11.43 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
9.85 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 57% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Acrotech Biopharma Inc., Amgen Inc., AstraZeneca Plc, Celltrion Healthcare Co. Ltd., F. Hoffmann La Roche Ltd., Fosun International Ltd., Genmab AS, IGM Biosciences Inc., JSC BIOCAD, LFB SA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Spectrum Pharmaceuticals Inc., TG Therapeutics Inc., United BioPharma Inc., and ZHEJIANG HISUN PHARMACEUTICAL Co. Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
